J B Chemicals & Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 3d ago
Result Summary
- J B Chemicals & Pharmaceuticals Ltd reported a 1.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.5%.
- Its expenses for the quarter were down by 0.6% QoQ and up 8.3% YoY.
- The net profit decreased 4.8% QoQ and increased 21.8% YoY.
- The earnings per share (EPS) of J B Chemicals & Pharmaceuticals Ltd stood at 12.45 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1083.00 | 1100.24 | 971.49 | -1.6% | 11.5% |
Total Expenses | 816.13 | 821.09 | 753.50 | -0.6% | 8.3% |
Profit Before Tax | 266.87 | 279.15 | 217.99 | -4.4% | 22.4% |
Tax | 68.98 | 71.33 | 55.50 | -3.3% | 24.3% |
Profit After Tax | 197.89 | 207.82 | 162.49 | -4.8% | 21.8% |
Earnings Per Share | 12.45 | 13.08 | 10.24 | -4.8% | 21.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
J B Chemicals & Pharmaceuticals Ltd is a company that operates within the pharmaceutical industry. It is involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company is known for its focus on products that address various medical needs, including formulations for therapeutic areas like cardiology, gastroenterology, and anti-infectives. Recent developments in the company may include expansion of product lines or strategic partnerships, although specific details are not available in the provided data. The company is headquartered in India and has been a significant player in the pharmaceutical sector, contributing to healthcare through its diverse product offerings.
Revenue
During the third quarter of the fiscal year 2026 (Q3FY26), J B Chemicals & Pharmaceuticals Ltd reported a total income of ₹1083.00 crores. This represents a decrease of 1.6% compared to the previous quarter (Q2FY26), where the total income was ₹1100.24 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY25), there is a notable increase of 11.5% from ₹971.49 crores. These figures indicate the company's performance in generating revenue over different periods, showcasing its ability to achieve year-over-year growth despite a quarter-over-quarter decline.
Profitability
The company’s profitability for Q3FY26 is highlighted by a Profit Before Tax (PBT) of ₹266.87 crores, which is a decrease of 4.4% from Q2FY26, where PBT was ₹279.15 crores. Compared to Q3FY25, this represents an increase of 22.4% from ₹217.99 crores. The Profit After Tax (PAT) for Q3FY26 stands at ₹197.89 crores, marking a 4.8% decline from the previous quarter’s ₹207.82 crores, yet showing a 21.8% increase compared to the ₹162.49 crores reported in Q3FY25. The tax expenses for Q3FY26 were ₹68.98 crores, reflecting a decrease of 3.3% from the previous quarter, but a 24.3% increase year-over-year. These figures illustrate the company’s ability to maintain profitability despite fluctuations in quarterly performance.
Operating Metrics
The company’s financial performance is further detailed through its operating metrics, including Earnings Per Share (EPS), which was ₹12.45 for Q3FY26. This represents a decrease of 4.8% from the EPS of ₹13.08 reported in Q2FY26. However, compared to the EPS of ₹10.24 in Q3FY25, there is a significant increase of 21.6%. The total expenses for Q3FY26 were ₹816.13 crores, which is a slight decrease of 0.6% from ₹821.09 crores in Q2FY26, and an increase of 8.3% from ₹753.50 crores in Q3FY25. These metrics provide insight into the company's cost management and earnings dynamics over the specified periods.